Form 4: Ptc Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Glenn Steele Jr, a Director of Ptc Therapeutics, Inc., sold 12,000 shares of common stock on September 30, 2026 for $65.16 per share.
Summary
- Option exercise/conversion: acquired 12,000 Common Stock at $11.23 ($134,760) on September 30, 2026; holds 34,500 after (Direct).
- Open-market sale: disposed of 12,000 Common Stock at $65.16 ($781,920) on September 30, 2026; holds 22,500 after (Direct).
- Option exercise/conversion: disposed of 12,000 Stock Option (Right to Buy) on September 30, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $781,920 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Glenn Steele Jr — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Common Stock | 12,000 | $11 | $134.8K | 34,500 |
| 2026-09-30 | Open-market sale | Common Stock | 12,000 | $65 | $781.9K | 22,500 |
| 2026-09-30 | Option exercise/conversion | Stock Option (Right to Buy) | 12,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (12,000 shares) |
| 2026-09-30 | Open-market sale (12,000 shares) |
| 2026-09-30 | Option exercise/conversion (12,000 shares) |
Keywords
insider transaction, Form 4, PTCT, PTC THERAPEUTICS, INC., bearish, Glenn Steele Jr
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.